Results 61 to 70 of about 14,967 (152)

Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452.

PLoS ONE, 2018
Ticagrelor, a P2Y12 antagonist, is approved for prevention of thromboembolic events. MEDI2452 is a potential reversal agent for ticagrelor and ticagrelor active metabolite (TAM). The total plasma exposure of ticagrelor and TAM in patients are roughly 0.5-
Ann-Sofie Sandinge, Annika Janefeldt, Susanne Pehrsson, Sven Nylander   +3 more
doaj   +1 more source

Ticagrelor – toward more efficient platelet inhibition and beyond

Therapeutics and Clinical Risk Management, 2018
Michał J Kubisa,1 Mateusz P Jezewski,1 Aleksandra Gasecka,2,3 Jolanta M Siller-Matula,4 Marek Postuła1 1Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CEPT), 21st Chair and Department of Cardiology,
Kubisa MJ, Jezewski MP, Gasecka A, Siller-Matula JM, Postuła M   +4 more
doaj  

Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial

Cardiovascular Diabetology, 2019
Background Microvascular blood flow (MBF) impairment in patients with lower extremity arterial disease (LEAD) is associated with more severe major adverse limb events (MALE).
Robert S. Rosenson, Qinzhong Chen, Sherwin D. Najera, Prakash Krishnan, Martin L. Lee, Daniel J. Cho   +5 more
doaj   +1 more source

Ticagrelor for Asian patients with acute coronary syndrome in real-world practice: A systematic review and meta-analysis of observational studies

Indian Heart Journal, 2019
Objective: We aimed to assess the efficacy and safety of ticagrelor compared to clopidogrel in Asian patients with acute coronary syndrome (ACS) in real-world practice.
Akhmetzhan Maratovich Galimzhanov, Baurzhan Slymovich Azizov   +1 more
doaj   +1 more source

Comparison of Ticagrelor with Clopidogrel in Reducing Interleukin-17 and Myeloperoxidase Expression in Thrombus and Improving Postprocedural Coronary Flow in ST-segment Elevation Myocardial Infarction Patients

Journal of Pharmacy & Pharmaceutical Sciences, 2018
Purpose. This study aimed to explore the effects of ticagrelor (a P2Y12 receptor inhibitor) on interleukin (IL)-17 and myeloperoxidase (MPO) expression in coronary thrombus as well as on the coronary blood flow in ST-segment elevation myocardial ...
WenHua Li, SongQi Guo, Shu Wang, Xin Sun, ZhuQin Li, XinYong Sun, YanMing Sun, LanFeng Wang, Wei Pan   +8 more
doaj   +1 more source

Effect of Ticagrelor Versus Clopidogrel on Aortic Stiffness in Patients With Coronary Artery Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background We compared the acute and midterm effect of ticagrelor versus clopidogrel on aortic stiffness. Methods and Results We studied 117 patients in a randomized, assessor‐blinded, parallel‐group trial.
Charalambos Vlachopoulos, Christos Georgakopoulos, Panagiota Pietri, Nikolaos Ioakeimidis, Michael Koutouzis, Sophia Vaina, Konstantinos Aznaouridis, Konstantinos Toutouzas, George Latsios, Dimitrios Terentes‐Printzios, Aggeliki Rigatou, Dimitris Tousoulis   +11 more
doaj   +1 more source

Managing the Complex Intersection Between Substance Use Disorders and Infectious Diseases

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 3, March 2026.
Karissa Chow, Amanda Binkley, Jessica Meisner, Samantha Huo, Matthew Hinton   +4 more
wiley   +1 more source

Response to Tutorial Drug–Drug Interactions by EM Sellers

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
Jesmin Lohy Das, Antoinette (Toni) Ajavon‐Hartmann, Virginia (Ginny) D. Schmith   +2 more
wiley   +1 more source

Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis

Drug Design, Development and Therapy, 2016
Michael R Preusch,1 Jonas Rusnak,1 Kathrin Staudacher,2 Carolin Mogler,3 Lorenz Uhlmann,4 Philipp Sievers,1 Florian Bea,1 Hugo A Katus,1 Erwin Blessing,1 Ingo Staudacher1 1Department of Internal Medicine III, 2Department of Neonatology, 3Department of ...
Preusch MR, Rusnak J, Staudacher K, Mogler C, Uhlmann L, Sievers P, Bea F, Katus HA, Blessing E, Staudacher I   +9 more
doaj  

Ticagrelor versus clopidogrel in the management of acute myocardial infarction

Journal of Community Hospital Internal Medicine Perspectives, 2019
Hypothesis: In the care of acute myocardial infarction, ticagrelor attenuates post-ischemic myocardial damage and inhibits platelet activity to a greater extent than clopidogrel.
Candice Volney, Anthony Collins, Sarah Adams   +2 more
doaj   +1 more source